[Clinical application of 18F-FDG PET/CT in the treatment of sarcomas].
[18F]-Fluoro-deoxyglucose positron emission tomography / computer tomography (18F-FDG PET/CT) is able to detect and assess the abnormal metabolism, enabling visualization and quantification in vivo with integration into CT anatomic information. The clinical usefulness of FDG PET/CT in the management of patients with sarcomas has been assessed by numerous investigators. Sarcomas are solid malignant tumors with distinct clinical and pathological features. Effective management of patients with sarcoma requires accurate diagnosis and staging. The authors discuss the major indications of PET/CT on the basis of literature data for diagnosis, staging, guidance of biopsy and monitoring response to therapy in both primary bone and soft tissue tumors. The consistent use of PET molecular imaging methods is of high importance in characterizing and understanding sarcoma behavior in clinical practice.
PET/CT Ambulancia, Országos Onkológiai Intézet, Budapest, Hungary. katalin.borbely@oncol.hu.
Katalin
K
Borbély
Onkológiai Osztály, Szent Margit Kórház, Budapest, Hungary.
Zsuzsanna
Z
Németh
Igazgatóság, Országos Onkológiai Intézet, Budapest, Hungary.
Miklós
M
Kásler
D001706:Biopsy / Q000379:methods; D002471:Cell Transformation, Neoplastic / Q000378:metabolism; D003937:Diagnosis, Differential; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism* / Q000628:therapy; D049268:Positron-Emission Tomography / Q000379:methods; D011379:Prognosis; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18